您的位置: 首页 > 农业专利 > 详情页

DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
专利权人:
MERCK SHARP & DOHME CORP.
发明人:
SEBHAT, Iyassu, K,ARASAPPAN, Ashok,DEMONG, Duane,HOYT, Scott, B,WILKENING, Robert, R.
申请号:
CR20190147
公开号:
CR20190147A
申请日:
2017.09.25
申请国别(地区):
CR
年份:
2019
代理人:
摘要:
The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V), and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild congnitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.La presente invención proporciona ciertos compuestos de cromano, isocromano y dihidroisobenzofurano sustituidos de fórmula (I): o una sal farmacéuticamente aceptable de los mismos, en la que el anillo A es un resto seleccionado de: y el anillo B, n, R1, R2, R2A, R3 y R3A son como se definen en la presente memoria. Los compuestos de la invención son útiles como 10 inhibidores de mGluR2, o moduladores alostéricos negativos de mGluR2 (NAM), y pueden ser útiles en procedimientos de tratamiento de un paciente para enfermedades o trastornos en los que está implicado el receptor mGluR2-NAM, tales como la enfermedad de Alzheimer, deterioro cognitivo, deterioro cognitivo leve, esquizofrenia y otros trastornos del estado de ánimo, trastornos del dolor y trastornos del sueño, medi
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充